The pathogenesis of primary and secondary CNS lymphoma poses a unique set of diagnostic, prognostic and therapeutic challenges. During the past ten years there has been significant progress in the elucidation of the molecular properties of CNS lymphomas and their microenvironment as well as evolution in the development of novel treatment strategies. Once assumed to be uniformly associated with a dismal prognosis, it is now reasonable to anticipate long-term survival and possibly cure for a significant fraction of CNS lymphoma patients. The pathogenesis of CNS lymphomas impacts multiple compartments within the neuroaxis and proper management of the CNS lymphoma patient requires a multidisciplinary team with expertise not only in Hematology/Oncology but also in Neurology, Neuroradiology, Neurosurgery, Clinical Neuropsychology, Ophthalmology, Pathology and Radiation Oncology. Given the evolving principles of management and the evidence for improvements in survival, our goal is to provide an overview of current knowledge regarding the pathogenesis of CNS lymphomas, and to highlight promising strategies that we believe to be most effective in establishing diagnosis, staging, as well as therapeutic management.
Introduction
Central nervous system (CNS) involvement of non-Hodgkin's lymphoma (NHL) occurs in two patterns: (1) primary CNS lymphoma (PCNSL) which is limited to the brain parenchyma, intraocular compartment, cranial nerves, leptomeninges, and rarely spinal cord;(1, 2) (2) secondary CNS lymphoma (SCNSL) in which there is concomitant systemic as well as CNS localization of lymphoma, often within the leptomeningeal compartment. PCNSL is a rare brain tumor with an annual incidence in the United States of approximately 1,900 new cases year. While PCNSL constitutes approximately 3% of all newly-diagnosed brain tumors, and 2-3% of all cases of non-Hodgkin's lymphoma (NHL), the Surveillance, Epidemiology and End Results (SEER) database suggests that the incidence of this neoplasm may be increasing among patients age sixty-five and older, with patients older than seventy-five having the highest incidental risk. may not be uniformly reflected in population-based data, there is a possibility that patients in the community may not routinely receive optimal therapy. Our goal in this review is to highlight areas of progress and to provide an overview of current knowledge regarding the pathogenesis of primary and secondary CNS lymphomas. In addition, we will illuminate strategies that we believe to be most effective in establishing diagnosis, staging, as well as in therapeutic management.
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Etiology of CNS Lymphomas
As for most other types of non-Hodgkin's lymphomas, the etiology of CNS lymphomagenesis is largely undefined and the mechanistic basis for brain tropism is not 
Histology and Molecular Pathogenesis
Among immunocompetent patients, PCNSL usually presents as a solitary supratentorial mass within periventricular white matter, often with subependymal spread and significant vasogenic edema and mass effect: the displacement of normal brain structures. The frequency of multiple lesions is increased two-fold in the immune suppressed. It is well-established that the radiographic as well as gross appearance of the tumor underestimates the extent of disease as PCNSL can be highly-infiltrative,
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Approximately 95% of PCNSL tumors are CD20+ diffuse large B-cell lymphoma; less common histologies include T-cell PCNSL (2%) (13) , Burkitt, lymphoblastic, and intraparenchymal marginal zone lymphoma. Notably, dural-based marginal zone lymphomas, devoid of intraparenchymal extent, share overlapping radiographic features with meningioma and are not protected by the blood-brain barrier.
Nearly twenty percent of PCNSL cases present with intraocular involvement with cellular infiltrates in the vitreous, retina and with lymphoid hyperplasia of the uveal tract.
In some cases, thickened choroid invested with lymphoma may extend into the orbit. It is important to recognize that intraocular lymphoma progresses to clinically-evident CNS lymphoma in at least 80% of cases, and thus mandates staging procedures commensurate with this risk. (14) Montesinos-Rongen and colleagues demonstrated that PCNSL exhibits somatic hypermutation of genes such as BCL6, MYC, PIM1, PAX5, suggesting that the neoplastic cells of PCNSL DLBCL are derived from antigen-selected B-cells exposed to the germinal center,(15) and while only 10-20% are CD10 positive, between 50% to 80% of tumors express significant levels of BCL-6.(16) Nevertheless, these tumors exhibit a near-uniform activated B-cell like immunophenotype in that 95% stain positive for MUM-1, consistent with overlapping features of germinal center and activated B-cell phenotypes. (17) Determination of the unique genetic features of PCNSL poses a greater challenge than for systemic DLBCL, both because of the rarity of this neoplasm and because of the paucity of material available for investigational studies after the diagnosis CSF concentration of CXCL13 as well as IL-10 may also be useful in facilitating the diagnosis of CNS lymphoma, both at diagnosis as well as relapse. (38) Transcriptional profile studies of PCNSL have identified a number of potential mediators of disease pathogenesis including upregulated expression of MYC. (19) Evidence for increased MYC expression was also observed in an independent immunohistochemical analysis of diagnostic specimens of PCNSL patients enrolled in CALGB (Alliance) 50202. 
Clinical Presentation
In a recent retrospective series of patients with a history of rapidly progressive neurological deterioration who presented for diagnostic brain biopsy, the most common etiology was PCNSL (20%). Among immunocompetent patients, the median age at diagnosis of PCNSL is 56 years with a male-to-female ratio of 1.2-1.7:1. The clinical presentation of PCNSL usually reflects the neuroanatomical location of the lesion(s). 
Diagnostic and Staging Evaluation
Because CNS and intraocular lymphoma patients typically present with nonspecific signs and symptoms, establishing a diagnosis may be difficult. A magnetic resonance-based examination of the brain, with gadolinium contrast, is the recommended first imaging test in diagnostic evaluation. In 95% of cases, there is homogenous enhancement localized to the tumor with rare necrosis, one of the radiographic features that helps to distinguish CNS lymphomas from glioblastoma.
Among immunocompetent patients with newly-diagnosed PCNSL, lesions are solitary in 65% and multifocal in 35%. Cerebral hemisphere disease is most common (38%) followed by lesions within the thalamus/basal/ganglia (16%), corpus callosum (14%) ventricular region (12%) and cerebellum (9%). (46) (Figure 2 The most commonly used diagnostic approach for PCNSL is stereotactic brain biopsy, in selected cases however, partial or gross total resections may be appropriate. 
Whole Brain Radiation
In general, whole brain irradiation is highly effective in the generation of immediate responses to patients with CNS lymphoma and therefore this modality historically has been of value to patients who otherwise experienced a rapidly deteriorating course caused by an unusual type of brain tumor rarely encountered in community practice.
The utility of whole brain radiotherapy in the treatment of CNS lymphoma is however limited by at least three factors: (1) Insufficient local control of lymphoma; (2) Dissemination of lymphoma cells within the CSF circulation, outside of the radiation field; (3) Detrimental effects of radiation on brain function. In one study, the use of whole brain radiation therapy as the sole treatment of PCNSL (36-40 Gy) yielded an overall response rate of 90% but a median overall survival of only 11.6 months with over 60% of patients experiencing progression of lymphoma within the irradiated field. (61) There is also increasing recognition of the long-term neurotoxicity of whole brain radiotherapy which, as illustrated by Abrey and colleagues, is manifest by incontinence, gait and memory disturbances. In their series, patients age older than 60 years were most vulnerable to this complication and many required custodial care to manage this treatment-related toxicity.(62) While there is evidence that lower doses of whole brain radiotherapy may cause less discernable neurotoxicity compared to standard doses, additional validation is necessary and based upon the evidence of deleterious neurocognitive effects of prophylactic cranial irradiation at 30 Gy, (63) it is logical to postulate that radiation-induced neurotoxicity may be a continuous variable. Certainly
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Induction Chemotherapeutic Strategies
Studies To date, however, the optimal high-dose regimen for methotrexate has not been firmly defined. In our experience, doses greater than or equal to 1 gm/m 2 achieve At present, there are no evidence-based guidelines that dictate the optimal number of high-dose methotrexate cycles to be administered at diagnosis. There is however, evidence which suggests that greater than four cycles of methotrexate-based therapy may be necessary to obtain a significant remission before using non-cross- (Table 2) . Notably, results obtained using the BEAM combination regimen followed by autologous stem cell rescue were not promising in a single institution study. (69) Soussain and colleagues described one of the earliest series to demonstrate the efficacy of high-dose chemotherapy and autologous stem cell transplant in salvage of recurrent CNS and intraocular lymphoma. One of the key findings of this study was the observation that the combination of etoposide plus high-dose cytarabine was highly active as first-line salvage therapy in recurrent/refractory CNS lymphomas, with 12 of 14 patients exhibiting responses, eight of which were complete responses (79) . After stem cell collection, responding patients on the trial were treated with a myeloablative regimen consisting of thiotepa, busulfan and cyclophosphamide.
In early 2001, our group at the University of California, San Francisco (UCSF), began to pursue high-dose chemotherapy as first-line consolidation in patients with newly-diagnosed PCNSL. We developed a two-step regimen, designed to be tolerated by the majority of PCNSL patients, particularly during the month post diagnosis when performance status and neurologic function are most compromised. The regimen involves 4 months of induction therapy using intravenous high-dose methotrexate given every two weeks with oral temozolomide and intravenous rituximab (MT-R) followed by high-dose consolidation, without WBRT. Methotrexate is administered at a target dose The two-year rate of progression-free survival in this multicenter study, 0.57, exceeds those of other chemotherapy-alone studies and the median time to progression of all 50202 patients, four years, is two-times longer than achieved with combined-modality therapy in multicenter trials using standard-dose whole brain radiotherapy. (74, 78) In addition, for the first time in a multicenter trial in PCNSL conducted by a cooperative group, the progression-free survival curves showed evidence of a stable plateau, and with a median follow-up of greater than five years, the median overall survival has not been reached. The overall survival for the cohort that completed dose-intensive consolidation with EA was particularly promising, and confirmed institutional data.(9) (Figure 5 ) Moreover, the regimen was well-tolerated, with only 10% of patients experiencing grade 4 neutropenia during induction. As expected however, high-dose consolidation was associated with a greater than 80% rate of grade 1 9 4 neutropenia and thrombocytopenia and all patients received growth factor and antibiotic support during consolidation. The one treatment-related mortality in the study was a grade 5 septic event during a neutropenic nadir from intensive consolidation in a subject managed as an outpatient, underscoring our recommendation for detailed inpatient monitoring during the consolidation phase until count recovery. Importantly there were no reported cases of severe neurotoxicity in the trial, despite the high-doses of cytarabine administered, however detailed neurocognitive evaluations were not performed. A flow-chart, depicting our diagnostic and therapeutic approach, is presented in Figure 4 . 
Treatment of Synchronous Brain and Systemic Lymphoma at Diagnosis
Our approach to the treatment of patients with synchronous brain parenchymal Table 2 ).
For
Notably however, patients with disease that has relapsed within six months of EA or other dose-intensive regimens used to consolidate a first remission of PCNSL may not be good candidates for second-line high-dose chemotherapeutic salvage approaches.
We offer investigational therapeutic trials or reserve whole brain radiotherapy primarily for such patients as well as for those with demonstrated methotrexate resistance.
The role of rituximab in CNS lymphomas
While rituximab consistently improves outcomes in systemic B-cell non-Hodgkin's lymphoma (NHL), a number of reports suggest that the addition of rituximab to CHOP 
Treatment of Intraocular Lymphoma
Most cases of intraocular lymphomas are of diffuse large B-cell type, either primary vitreoretinal lymphoma or uveal lymphomas, which themselves can be subdivided into primary neoplasms of the choroid, iris and ciliary body or secondary choroidal lymphomas in patients with disseminated NHL. These types of B-cell neoplasms are to be distinguished from marginal zone lymphomas that tend to present in the ocular adnexa, e.g. the conjunctiva, and which do not pose a high risk of CNS dissemination. Notably, intraocular lymphoma impacts between 15-25% of patients with here again, the optimal approach has not been defined. (Table 3) 
Treatment of CNS Lymphoma in the Immunocompromised Host
While the incidence of HIV-associated PCNSL has declined markedly with the advent of highly-active antiretroviral therapy (HAART), PCNSL continues to be a 
Conclusions and Future Directions
The past 20 years has witnessed remarkable changes in the incidence, epidemiology, natural history and prognosis for patients with PCNSL, an adult brain tumor previously considered to be incurable and closely linked to the HIV epidemic. It now appears that the incidence of PCNSL is increasing in a population age greater than 60 years, without clinically overt immunosuppression. Moreover, there is reproducible evidence that by judicious application of established agents and their empiric refinement within combination regimens, long-term survival and cure can be anticipated in approximately 50% of patients.
In particular, an accumulation of studies show encouraging survival in newly-diagnosed patients treated without whole brain radiotherapy as consolidation. There is also evidence for progress in the treatment of What dose-intensive consolidation and/or preparative regimen is most effective and has the most acceptable toxicity profile in terms of myelosuppression, as well as gastrointestinal and neurotoxicity ? ( Table 2) Nevertheless, it is highly likely that therapeutic outcomes have now achieved a plateau with existing genotoxic strategies and that further innovations are urgently needed to facilitate diagnosis, prevention and/or treatment of primary and secondary CNS lymphomas, especially given their predilection for an aging population among whom a significant proportion can not tolerate high-dose chemotherapy and/or whole brain radiotherapy. As patients with CNS lymphoma are living longer, there is also a greater need to begin to address quality-of-life issues including cognitive dysfunction that can occur as a result of disease and treatments.
There is also significant need for novel biomarkers that identify high-risk patient subpopulations, particularly the 20-25% of patients who exhibit primary refractory disease during the first six months and the additional 20% of patients who achieve Figure 4 . How I Treat Primary CNS Lymphoma. In the diagnostic workup, an MRI of the spine (+/-gadolinium) may be useful if warranted by neurologic symptoms or if CSF analysis is contraindicated. Testes ultrasound is indicated for older male patients with CNS involvement of lymphoma in which testes co-involvement is suspected on clinical and/or radiographic grounds. The value of PET scan in this setting is not established. While the schedule of decadron taper should be individualized for each patient, we recommend a planned taper to be completed within 2-3 weeks of diagnosis, between the first and second courses of HD-methotrexate. Therapeutic options for indolent lymphomas that involve the CNS or dura include rituximab, fludarabine, involved-field irradiation, and high-dose methotrexate for CNS involvement of CLL/SLL. For newly-diagnosed patients who are not candidates for HD-methotrexate, in most cases we recommend a trial of temozolomide and rituximab and/or strategies that employ high-dose chemotherapy, before consideration of whole brain irradiation. Abbreviations: PCP, pneumocytis carinii; HSV, herpes simplex virus; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; MT-R, combination high-dose methotrexate, temozolomide, and rituximab (rituximab is omitted for T-cell lymphomas); EA, etoposide-cytarabine; WBRT, whole brain radiotherapy; ASCT, autologous stem cell transplant.
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Progress in the Treatment of Primary CNS Lymphoma. Comparison of outcomes for newly-diagnosed primary CNS lymphoma in two multicenter cooperative group clinical trials. (A) Combined modality therapy with whole brain radiotherapy in RTOG-9310 resulted in median progression-free survival of two years with a significant rate of disease progression beyond two years.
For personal use only. on . by guest www.bloodjournal.org From Immunochemotherapy with rituximab plus intensive consolidation, CALGB (Alliance) 50202, resulted in a median progression-free survival of four years with evidence for a stable plateau in the survival curve. (C) Progression-free survival was particularly encouraging for the 65% of patients who received both induction plus consolidation treatment modules of CALGB (Alliance) 50202.
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